Evaluation of a Pilot Shard-care Program for Patients With Chronic Pain in the Champlain-LHIN (Shared-Care)
29 de abril de 2022 actualizado por: Ottawa Hospital Research Institute
The study is evaluating an intervention consisting of a five week online mindfulness program for patients being referred to the Pain Clinic and triaged to eConsult.
A pain specialist will be in contact with the patient's family physician to confirm it's appropriate and then a therapist will initiate contact with the patient to assess eligibility.
The therapist will be a registered health professional with experience with patients with chronic health problems and will be supporting the online program where the participant will have communication access to them.
Questionnaires will be sent at three time points to assess changes.
Descripción general del estudio
Estado
Aún no reclutando
Condiciones
Intervención / Tratamiento
Descripción detallada
There are currently many patients waiting to be seen at The Ottawa Hospital Pain Clinic (TOHPC). However, many patients with chronic pain (CP) have exhausted medical options or could be served in the community with appropriate support for them and their family physicians (FPs). eConsult is a secure web-based platform that allows TOHPC physicians to provide pain management advice within seven days within the Champlain Local Health Integration Network (LHIN).
In order to provide enhanced care to patients and improve the uptake of eConsult for CP, the investigators have developed a shared care model for CP in the Champlain LHIN. This program combines the use of eConsult for FPs and a 5-week self-directed online CP management program with therapist support available as needed.
Tipo de estudio
Intervencionista
Inscripción (Anticipado)
240
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Estudio Contacto
- Nombre: Patricia Poulin, PhD C. Psych
- Número de teléfono: 73903 6137378899
- Correo electrónico: ppoulin@toh.ca
Ubicaciones de estudio
-
-
Ontario
-
Ottawa, Ontario, Canadá, K1H8L6
- Ottawa Hospital Research Institute
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
Inclusion Criteria:
- aged 18-years or older
- ability to understand oral and written English
- report chronic pain (≥3months)
Exclusion Criteria:
- refusal or inability to provide informed consent
- severe, unstable or untreated psychiatric conditions (ex. severe depression, psychosis, bipolar, etc.)
- does not have access to the internet or electronic device capable of watching videos
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Online chronic pain management program
There is only one arm.
Those who consent to participate in the study and take the online self-directed chronic pain management program with therapist support.
|
With the support of a study therapist, the participant will be enrolled in a 5 week self-directed pain management program.
The study therapist is a registered health professional.
The program will consist of 5 weeks of mindfulness training.
The mindfulness training focuses on the basics of mindfulness-based interventions including body, emotions, sensations, thoughts, compassion, pain and stress management.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in mean score of the Brief Pain Inventory-Interference Scale (BPI-I)
Periodo de tiempo: At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
The interference scale measures the degree to which pain interferes in the lives of participants in 7 domains: general activity, mood, walking ability, normal work, relations with other persons, sleep and enjoyment of life on a scale from 0 to 10.
The higher the score, the greater the pain interferes with patient's activities.This is a well-validated measure of pain-related disability.
The minimum clinically significant difference is 1 point.
|
At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in pain intensity, as measured by the Brief Pain Inventory.
Periodo de tiempo: At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
The Brief Pain Inventory (BPI) Pain Severity Scale measures the severity of pain one feels at worst, at least, on average, and at the time of questionnaire completion on a scale from 0 to 10.
The higher the score, the greater the pain severity.
|
At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
|
Change in pain catastrophizing, as measured by the Pain Catastrophizing Scale
Periodo de tiempo: At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
The Pain Catastrophizing Scale (PCS) is a 13-item instrument which will evaluate the degree to which patients have negative self-statements and catastrophizing thoughts and ideations when in pain.
The PCS uses a 5-point likert scale (0=not at all, 4=all the time) and consists of three subscales (rumination, magnification, helplessness).
|
At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
|
Change in mindfulness, as measured by the Short Form Five Facet Mindfulness Questionnaire.
Periodo de tiempo: At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
Mindfulness will be measured using the Short Form Five Facet Mindfulness Questionnaire (FFMQ-SF).
The FFMQ-SF is a 24-item instrument measuring five aspects of mindfulness: Non-reactivity to inner experience, observing, describing, acting with awareness, and non-judging of experience.
Participants are asked to use a 5-point Likert-type scale (1 = never or rarely true; 5 = very often or always true) to rate how true of them they believe each statement to be.
|
At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
|
Change in quality of life, as measured by the EuroQOL-5D
Periodo de tiempo: At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
The EuroQOL-5D (EQ-5D) is a simple-to-use, valid, and sensitive instrument measuring quality of life.
It covers 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Each dimension has 3 levels: no problems, some problems, or severe problems and participants use a tick box to select the statement that is most representative of their conditions.
Participants are also asked to rate, using a visual analogue scale (0 to 100), their state of health.
|
At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
|
Change from baseline in depressive symptoms, as measured by the Patient Health Questionnaire - 9 scale
Periodo de tiempo: At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
The Patient Health Questionnaire - 9 (PHQ-9) is a 9-item scale used to assess the severity of depressive symptoms over the past two weeks and is based on Diagnostic and Statistical Manual (DSM-IV) diagnostic criteria for major depression.
Total scores range from 0 to 27, and clinical cut-points correspond to mild, moderate, moderately severe, and severe depression.
|
At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
|
Overall change in status from baseline, as measured by Patient Global Impression of Change scale
Periodo de tiempo: At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
The participants' perceived degree of change in overall status will be measured using the Patient Global Impression of Change (PGIC) scale.
The PGIC uses a 7-point likert scale (very much worse, to very much better) to measure how much the participant feels their overall status has changed since the start of the study.
|
At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
|
Change from baseline in anxiety symptoms, as measured by the Generalized Anxiety Disorder-7
Periodo de tiempo: At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
The Generalized Anxiety Disorder - 7 (GAD-7) is a 7-item scale used to assess the severity of anxiety symptoms over the past two weeks.
Total scores range from 0 to 15, and clinical cut-points correspond to mild, moderate, and severe anxiety.
|
At enrollment prior to the program, 2 weeks post-program, and at a 3-month follow-up after the program
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Investigador principal: Patricia Poulin, PhD C. Psych, Ottawa Hospital Research Institute
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Anticipado)
1 de septiembre de 2022
Finalización primaria (Anticipado)
1 de marzo de 2023
Finalización del estudio (Anticipado)
1 de marzo de 2023
Fechas de registro del estudio
Enviado por primera vez
19 de marzo de 2018
Primero enviado que cumplió con los criterios de control de calidad
8 de mayo de 2018
Publicado por primera vez (Actual)
21 de mayo de 2018
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
2 de mayo de 2022
Última actualización enviada que cumplió con los criterios de control de calidad
29 de abril de 2022
Última verificación
1 de abril de 2022
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- 20180238-01H
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
NO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .